Urothelial Carcinoma — Trials

Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 236
Recruiting: 117
Ph III recruiting: 14
Growth YoY: +37.5%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (99)

clinicaltrialsPublishedShowing 1–50 of 153 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05562830	A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)	recruiting	Phase 1 / Phase 2	48	Merck Sharp & Dohme LLCINDUSTRY	11	Sep 28, 2026	clinicaltrials
NCT06770582	Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial	recruiting	Phase 2	160	National Cancer Institute (NCI)NIH	2